Payers Question CMS’ Ability to Get Discounts Though Drug Price Negotiation
March 19th 2024In a recent survey, payers said the Inflation Reduction Act will help lower patients’ out-of-pocket costs, but they were concerned about Medicare’s drug price negotiation and the IRA’s impact on formulary management.
Read More
FDA Updates for Week of March 11: First CAR-T for CLL/SLL and First NASH Treatment
March 16th 2024The FDA this week approved a few firsts: the first treatment for NASH and the first CAR-T cell therapy for CLL/SLL. Other approvals include Tevimbra for esophageal cancer; Livmarli for second liver disease indication; and Praluent for children with genetic form of high cholesterol. The FDA also issued a CRL for monthly MS drug. Additionally, Celltrion submitted an application for an interchangeable Xolair biosimilar.
Read More
Michigan is First Medicaid Program to Offer Lyfgenia for Sickle Cell
March 11th 2024Michigan’s state Medicaid agency has signed an outcomes-based agreement for Lyfgenia patients with sickle cell disease. The agreement provides payers with risk sharing tied to vaso-occlusive events-related hospitalizations
Read More
Oral Drug for Hidradenitis Suppurativa Shows Promise in Small Study | AAD 2024
March 9th 2024A phase 2 study demonstrated positive results for remibrutinib, a BTK inhibitor, as a treatment for patients with the rare skin condition, hidradenitis suppurativa, finds a study presented at the American Academy of Dermatology Association.
Read More
FDA Updates for Week of March 4, 2024: Wegovy Gets New Indication
March 9th 2024The FDA has approved Wegovy for reducing cardiovascular risks in people who are obese or overweights. The agency approved new biosimilars that reference Actema, Prolia and Xgeva. Additionally, the FDA plans to hold advisory committee meeting for donanemab in Alzheimer’s disease.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More
Socioeconomic Status Is the Biggest Reason Women Don’t Get Breast Cancer Screening
March 5th 2024Women experiencing high levels of poverty and those in impoverished rural regions are less likely to get screened for breast cancer, find a new review of studies that have assessed social determinants of health.
Read More
FDA has expanded the indication for Biktarvy for those with resistant HIV, granted full approval to Rybrevant and approved Simlandi, the third interchangeable Humira biosimilar. The regulatory agency has also set action dates for sxatilimab in graft-versus-host disease, tislelizumab in stomach cancer and a second indication for Epkinly.
Read More